Latest News-Deqi(Zhejiang)Pharmaceutical Technology Co. Ltd. Mediaroom_Page

Antengene Announces Research Collaboration with Celularity to Evaluate the Potential Therapeutic Synergy of Combining Antengene's Best-in-Class Bispecific Antibody with Celularity's Natural Killer Cell Platform

- This research collaboration marks Antengene's entry into the field of cellular medicines. SHANGH...

2022-07-19 18:00 2083

Antengene Announces Clinical Trial Collaboration with BeiGene to Evaluate Selinexor in Combination with Tislelizumab in T and NK-Cell Lymphoma

- Selinexor is an oral small molecule XPO1 inhibitor; tislelizumab is an anti-PD-1 checkpoint in...

2022-06-27 08:30 2594

Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors

SHANGHAI and HONG KONG, June 8, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-06-08 08:30 2130

Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018

– Discovered in-house by the internal R&D Team at Antengene, ATG-018 is an orally-bioavailable, sma...

2022-06-07 11:34 2636

Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 American Society of Clinical Oncology Annual Meeting

Poster will report data from the Phase I/II TORCH-2 Study that evaluates ATG-008 (onataseritb) and ...

2022-06-01 08:30 2908

Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

SHANGHAI and HONG KONG, May 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-05-23 10:10 2974

Antengene Announces XPOVIO® Treatment Regimens Included for the First Time in the Guidelines for the Diagnosis and Management of Multiple Myeloma in China

SHANGHAI and HONG KONG, May 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-05-18 15:01 2867

Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China

-Distribution channels in place to streamline/facilitate patient access. -XPOVIO® will be available...

2022-05-16 11:20 3196

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-05-13 18:00 3246

Antengene Announces Addition of Multiple XPOVIO® Treatment Regimens for Myeloma and Lymphoma in 2022 CSCO Guidelines

SHANGHAI and HONG KONG, May 13, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEH...

2022-05-13 08:30 2963

Antengene to Participate in Three Upcoming Investor Conferences in May/June

CICC Healthcare Industry Forum 2022: May 9th to 12th BTIG Virtual China Biotech Day: June 1st Citi...

2022-05-06 08:30 2725

Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting

SHANGHAI and HONG KONG, April 29, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2022-04-29 22:30 2982

Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018

* Developed in-house by internal R&D Team at Antengene, ATG-018 is an orally-available, small mol...

2022-04-27 08:30 2116

Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

The company will present the preclinical data of five novel drug candidates at AACR 2022 (onApril 8...

2022-04-11 08:30 2568

Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Antengene's Pivotal "MARCH" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine

- Results showed an overall response rate (ORR) of 29.3% for all treated patients. - Consistent res...

2022-04-06 20:03 2995

Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes

* This study is the third ATG-016 study to be conducted in China. * Study highlights Antengene's...

2022-03-30 09:00 2171

Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates

SHANGHAI and HONG KONG, March 18, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" S...

2022-03-18 22:12 6041

Antengene Announces IND Approval in China for the Phase I Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

- The novel bispecific antibody ATG-101 is Antengene's first in house developed molecule with glob...

2022-03-10 08:52 2541

Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting

* Posters Showcase Early-Stage Clinical and Preclinical Pipeline. * Focus on ATG-037, ATG-018, A...

2022-03-09 20:00 2686

Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma

- XPOVIO®, in combination with bortezomib and dexamethasone (XBd), gives patients with relapsed an...

2022-03-09 19:08 2464